Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.

Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I.

Hum Gene Ther. 2008 Oct;19(10):991-9. doi: 10.1089/hum.2008.131.

PMID:
18713023
2.

Drug delivery-mediated control of RNA immunostimulation.

Nguyen DN, Chen SC, Lu J, Goldberg M, Kim P, Sprague A, Novobrantseva T, Sherman J, Shulga-Morskaya S, de Fougerolles A, Chen J, Langer R, Anderson DG.

Mol Ther. 2009 Sep;17(9):1555-62. doi: 10.1038/mt.2009.147.

3.

Bifunctional siRNA containing immunostimulatory motif enhances protection against pandemic H1N1 virus infection.

Joshi G, Dash PK, Agarwal A, Sharma S, Parida M.

Curr Gene Ther. 2015;15(5):492-502.

PMID:
26264705
4.

Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.

Broering R, Real CI, John MJ, Jahn-Hofmann K, Ickenstein LM, Kleinehr K, Paul A, Gibbert K, Dittmer U, Gerken G, Schlaak JF.

Int Immunol. 2014 Jan;26(1):35-46. doi: 10.1093/intimm/dxt040.

5.
6.

Influenza A virus infection of human respiratory cells induces primary microRNA expression.

Buggele WA, Johnson KE, Horvath CM.

J Biol Chem. 2012 Sep 7;287(37):31027-40. doi: 10.1074/jbc.M112.387670.

7.

Induction of interferon lambda in influenza a virus infected cells treated with shRNAs against M1 transcript.

Švančarová P, Svetlíková D, Betáková T.

Acta Virol. 2015 Jun;59(2):148-55.

PMID:
26104331
8.

siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.

Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA.

Immunol Cell Biol. 2012 Feb;90(2):187-96. doi: 10.1038/icb.2011.19.

PMID:
21423261
9.

Inhibition of influenza virus production in virus-infected mice by RNA interference.

Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J.

Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8676-81.

10.

Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J.

Nature. 2008 Apr 3;452(7187):591-7. doi: 10.1038/nature06765.

11.
12.

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.

Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I.

Nat Biotechnol. 2005 Apr;23(4):457-62.

PMID:
15778705
13.

The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus.

ElHefnawi M, Hassan N, Kamar M, Siam R, Remoli AL, El-Azab I, AlAidy O, Marsili G, Sgarbanti M.

Bioinformatics. 2011 Dec 15;27(24):3364-70. doi: 10.1093/bioinformatics/btr555.

14.

Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.

Zhou H, Jin M, Yu Z, Xu X, Peng Y, Wu H, Liu J, Liu H, Cao S, Chen H.

Antiviral Res. 2007 Nov;76(2):186-93.

PMID:
17719657
15.

A potential therapeutic for pandemic influenza using RNA interference.

Seth S, Templin MV, Severson G, Baturevych O.

Methods Mol Biol. 2010;623:397-422. doi: 10.1007/978-1-60761-588-0_26.

PMID:
20217566
16.

Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.

Mook OR, Baas F, de Wissel MB, Fluiter K.

Mol Cancer Ther. 2007 Mar;6(3):833-43.

17.

Overcoming the innate immune response to small interfering RNA.

Judge A, MacLachlan I.

Hum Gene Ther. 2008 Feb;19(2):111-24. doi: 10.1089/hum.2007.179. Review.

PMID:
18230025
18.

RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids.

Zhou K, He H, Wu Y, Duan M.

J Biotechnol. 2008 Jun 1;135(2):140-4. doi: 10.1016/j.jbiotec.2008.03.007.

PMID:
18456361
19.

Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs.

Shin D, Kim SI, Park M, Kim M.

Biochem Biophys Res Commun. 2007 Dec 21;364(3):436-42.

PMID:
17963721
20.
Items per page

Supplemental Content

Support Center